This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baxter, S. W. Articles by Campbell, I. G. Search for Related Content PubMed PubMed Citation Articles by Baxter, S. W. Articles by Campbell, I. G.

Transforming Growth Factor ß Receptor 1 Polyalanine Polymorphism and Exon 5 Mutation Analysis in Breast and Ovarian Cancer

Cancer Genetics Laboratory, Victorian Breast Cancer Research Consortium, Peter MacCallum Cancer Institute, St. Andrews Place, East Melbourne, Victoria 3002, Australia [S. W. B., D. Y. H. C., I. G. C.]. Wessex Clinical Genetics Service, Princess Anne Hospital, Southhampton, SO16 5YA, United Kingdom [D. M. E.]

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
The inactivation or altered expression of TGF-ß receptors or other components of the TGF-ß signaling pathway are common in many cancer types. A germ-line sequence variant of transforming growth factor-ß receptor-1 (TßR-I), which involves the deletion of three alanines (6A) from a nine-alanine stretch (9A), has impaired mediation of TGF-ß antiproliferative signaling. The TßR-I (6A) variant has been reported to occur at an increased frequency in a variety of cancer types and may represent an important hereditary predisposing factor. We have investigated the possible influence of the TßR-I (6A) allele on cancer risk in a cases-control study of 248 controls; 304 women with ovarian cancer; 98 women with endometriosis; and 355 women with breast cancer occurring under the age of 40 years, bilateral breast cancer, or a family history of breast cancer. The TßR-I (6A) allele was significantly associated with breast cancer (odds ratio, 1.6; 95% confidence interval, 1.1–2.5). There was no significant association of this allele with ovarian cancers as a whole, although stratifying according to their histological subtype revealed a significant association with the endometrioid and clear-cell cancers (odds ratio, 2.1; 95% confidence interval, 1.2–3.6). Recently a recurrent somatic CTCTGGCTGCGTGG insertion mutation in exon 5 of TßR-I was reported in >30% of ovarian cancers. If verified, this would indicate that inactivation of TßR-I is a key step in the development of ovarian cancer, perhaps second only to the inactivation of TP53. We analyzed 55 ovarian and 33 breast cancers for mutations using both single-stranded conformational polymorphism/heteroduplex analysis and direct sequencing. No somatic mutations in exon 5 of TßR-I were detected in any case. Our study provides additional evidence for an association of the TßR-I (6A) allele with cancer predisposition, but we find no evidence of a mutational hot-spot in exon 5 of TßR-I in either ovarian or breast cancers.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Members of the TGF-ß² superfamily are potent regulators of cell growth and differentiation and have been shown to play important roles in the development of cancer. Evidence suggests that most of the activities of TGF-ß are mediated by binding to the TßR-I and TßR-II receptors, which are transmembrane serine/threonine kinases. TGF-ß inhibits the proliferation of normal epithelial cells, but the majority of neoplastic cell lines are resistant to these effects. TGF-ß resistance can occur via different mechanisms, including changes in the expression levels of functional TGF-ß or inactivation of the type I and II receptors and other downstream components of the signaling cascade. Somatic mutations in TßR-II have been identified in many tumor types, including colorectal cancers (1) , endometrial cancers (2) , and gliomas (3) . Mutations in TßR-I are less common, although a low frequency of mutations have been identified in prostate cancer cells (4) , breast cancer (5) , and ovarian cancer (6) . Recently Wang et al. (7) reported the identification of a recurrent CTCTGGCTGCGTGG insertion mutation in exon 5 of TßR-I in >30% of ovarian cancers. If verified, this would indicate that the inactivation of TßR-I is a key step in the development of ovarian cancer, perhaps second only to the inactivation of TP53. In light of this data, the existence of a common germ-line sequence variant of TßR-I with impaired mediation of TGF-ß antiproliferative signaling was particularly interesting. The polymorphism involves the deletion of three alanines from a nine-alanine stretch that encompasses the predicted signal sequence and the cytoplasmic region of TßR-I. Pasche et al. (8) speculated that the six-alanine variant, TßR-I (6A), might represent a cancer predisposing allele based on a higher-than-expected number of TßR-I (6A) homozygotes among cancer patients compared with controls. A subsequent larger study by the same investigators confirmed a significantly higher-than-expected frequency of TßR-I (6A) homozygotes and TßR-I (6A)/TßR-I (9A) heterozygotes among 851 cancer cases compared with 735 controls (9) . The most striking association was observed among colorectal cancers, in which 4 of 112 cases were TßR-I (6A) homozygotes compared with none among the 735 controls. Pasche et al. (9) also studied a small number of breast and ovarian cancers and these, too, showed an elevated frequency of TßR-I (6A) alleles, although this did not reach statistical significance.

In the present study, we investigated the possible influence of the TßR-I (6A) allele on cancer risk in a case-control study of 355 breast cancer cases, 304 ovarian cancer cases, 98 endometriosis cases, and 248 controls. In addition, we analyzed 55 epithelial ovarian cancers and 33 breast cancers for somatic mutations in exon 5 of TßR-I and, in particular, for the presence of the CTCTGGCTGCGTGG insertion mutation.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cancer Cases and Controls.
All of the cases and controls used for genotyping were residents in and around Southampton, United Kingdom and were of similar ethnic and geographical background. The endometriosis, breast cancer, and ovarian cancer cases represent a sequential series of patients. Incident cases of ovarian carcinomas (n = 304) and endometriosis (n = 98) were ascertained from women undergoing primary surgery for these diseases in hospitals in and around Southampton between 1993 and 1998. In each case, the histological diagnosis was confirmed by a specialist gynecological pathologist. The ovarian cancers studied consisted of 130 serous, 40 mucinous, 93 endometrioid or clear cell, and 41 undifferentiated adenocarcinomas. The age range of the ovarian cancer patients was 23–92 with a mean of 62 years, and for the endometriosis patients, the range was 20–78 with a mean of 42 years. The age range of the serous ovarian cancers was 23–87 (mean, 61 years), 32–91 years (mean, 62 years) for the mucinous cancers, 31–92 years (mean, 63 years) for the endometrioid/clear cell cancers (mean, 63 years), and 40–76 years (mean, 61 years) for the undifferentiated cancers. Three hundred fifty-five breast cancer cases were selected on the basis of an age at onset under 40 years, a family history of breast cancer (defined as two or more cases of breast cancer in a first- or second-degree female relative) irrespective of age at onset, or bilateral breast cancer irrespective of family history or age at onset. The age range of the breast cancer cases was 19–79 with a mean age of 38 years. All of the controls (n = 248) were white female volunteers who were either staff at the Princess Anne Hospital (n = 117) or outpatients (n = 131) attending for obstetric-related conditions. The age of the controls ranged from 18 to 84 with a mean age of 39 years. For all of the groups, normal genomic DNA was prepared from blood lymphocytes. Epidemiological data, such as reproductive factors, oral contraceptive use, smoking, and obesity, were not available for either the cases or the controls. However, both control and cancer groups were drawn from the same geographical area, which is predominantly an Anglo-Saxon population. Genomic DNA from 33 breast tumors was kindly provided by Dr. Nick Hayward (Queensland Institute of Medical Research, Brisbane, Australia).

TßR-I Genotyping.
Amplification of the genomic sequence containing the GCG repeat was performed as described by Pasche et al. (8) using the exonic primers 5'-ccacaggcggtggcggcgggaccatg-3' and 5'-cgtcgcccccgggagcagcgccgc-3'. The forward primer was labeled with a fluorescent dye (FAM) to enable detection. The alleles were separated on a 6% denaturing polyacrylamide gel and were detected using a scanning laser fluorescence imager (Bio-Rad Molecular Imager FX). Control samples with a known genotype (confirmed by direct sequencing) were included in each PCR batch. In addition, genotyping of the TßR-I polymorphism was repeated in 20% of cases and 20% of the controls to assess the consistency of the PCR assay.

LOH Analysis.
LOH across the TßR-I locus at 9q22 was assessed using the microsatellite markers D9S283 (9q13–22) and D9S127 (9q31). PCR and LOH analyses was carried out as described previously (10) . The intensities of the alleles were quantitated using a phosphorimager (Bio-Rad Molecular Imager FX) and Quantity One software (Bio-Rad, Hercules, CA).

SSCP/HD Analysis.
TßR-I exon 5 amplification was carried out above in the presence of 0.05 mCi of [-³²P]dATP using primers 5'-atggtctgcagcccaacc-3' and 5'-gcctccaccttctattttc-3'. The samples were analyzed by SSCP/HD analysis through a 0.5x mutation detection enhancement gel matrix (BioWhittaker, Rockland, ME), as described previously (10) .

DNA Sequencing.
PCR products were purified using the Wizard PCR cleanup system (Promega) and sequenced with a Thermo-sequenase Cycle Sequencing kit (Amersham, Little Chalfont, United Kingdom).

Statistical Analysis.
Frequencies were analyzed (compared) using Fisher’s exact test. ORs and 95% CIs were calculated using the relevant 2 x 2 contingency tables. All of the statistical calculations were two-sided and performed using InStat version 3.01 (GraphPad Software, Inc., San Diego, CA).

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
TßR-I GCG Repeat Allele Distribution Among Breast and Ovarian Cancers, Endometriosis, and Controls.
An example of the GCG repeat analysis is shown in Figure 1 . The genotyping was repeated for a minimum of 20% of the cases and controls, and no discrepancies in the genotyping were revealed. The genotype distribution among the cases and controls is shown in Table 1 . There was no departure from Hardy-Weinberg equilibrium distribution within the control (P = 0.99), breast cancer (P = 0.79), ovarian cancer (P = 0.92), or endometriosis groups (P = 0.99). There was no evidence of an age-related variation in the TßR-I (6A) allele frequency, with 18.2% of control individuals ages <35 carrying at least one TßR-I (6A) allele compared with 17.9% among those ages >35.

View larger version (53K): [in this window] [in a new window]   Fig. 1. TßR-I polyalanine polymorphism PCR products separated on a 6% denaturing polyacrylamide gel. Arrows, the position of the TßR-I (9A) and TßR-I (6A) alleles. Lanes 1, 2, 4, 5, 8, 9, and 10, TßR-I (9A) homozygotes; Lanes 3 and 6, TßR-I (9A)/TßR-I (6A) heterozygotes; Lane 7, a TßR-I (6A) homozygote.

There was an increased risk of endometriosis among TßR-I (6A) heterozygotes (OR, 1.6) and TßR-I (6A) homozygotes (OR, 2.8), although in both instances, the OR spanned 1. Similarly, among the ovarian cancer cases as a whole, there was a nonsignificant increase in risk associated with carrying one (OR, 1.4) or two (OR, 2.6) TßR-I (6A) alleles. Stratifying the ovarian cancers according to histological subtype revealed a highly significant increase in the TßR-I (6A) allele frequency among the endometrioid and clear cell cancers versus the control group (0.172 versus 0.088; P = 0.002). The ORs for heterozygous and homozygous carriers of the TßR-I (6A) allele were 1.8 (95% CI, 1.0–3.1) and 7.8 (95% CI, 1.5–41.4), consistent with a gene-dosage effect. Overall, individuals who were either homozygous or heterozygous for the TßR-I (6A) allele had an OR of 2.1 (95% CI, 1.2–3.6) compared with those homozygous for the wild-type TßR-I (9A) allele. The TßR-I (6A) allele frequency among the mucinous tumors was higher than among the controls, but the numbers were small, and the increase was not statistically significant (P = 0.15). The TßR-I (6A) allele frequency and the genotype distribution among the serous and undifferentiated ovarian cancers were very similar to those of the controls.

LOH Analysis of 9q13–31.
The frequency of LOH on chromosome arm 9q among the 57 ovarian cancers informative for either D9S283 or D9S127 was 68% (39/57). Matching tumor DNA was available for 21 of the 62 ovarian cancer cases that were TßR-I (9A)/TßR-I (6A) heterozygotes. Three of the 21 heterozygotes showed LOH of the TßR-I (6A) allele, and 3 showed LOH of the TßR-I (9A) allele.

Mutation Analysis of TßR-I Exon 5.
Fifty-five ovarian cancers (26 serous, 6 mucinous, 19 endometrioid, and 4 undifferentiated) and 33 breast cancers were analyzed for somatic mutations in exon 5 of TßR-I and, in particular, for a CTCTGGCTGCGTGG insertion mutation that has been reported to occur in 30% of epithelial ovarian cancers (7) . We did not detect any aberrant SSCP/HD band shifts in exon 5 among either the breast or the ovarian cancers. Direct genomic sequencing of exon 5 was performed on 5 serous, 5 endometrioid, and 5 mucinous ovarian cancers. An additional six ovarian cancers (four serous, one endometrioid, and one mucinous) were sequenced with the GT tracks only, to identify any CTCTGGCTGCGTGG insertion mutations. Seven of the nine serous cancers and five of six endometrioid cancers showed LOH across 9q. We obtained clear sequence for all of the cases, and only wild-type sequence was detected.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
Functional germ-line allelic variants of genes with a known role in cancer development are plausible cancer predisposing factors. The TßR-I (6A) allele fulfills both of these criteria because somatic mutations in TßR-I have been reported in a variety of malignancies (4, 5, 6, 7) and the TßR-I (6A) variant has reduced TGF-ß antiproliferative effects (9) compared with the common TßR-I (9A) variant and the rare TßR-I (10A) variants. Heterozygotes for the TßR-I (6A) allele have been reported in 10% of eastern United States population controls (9 , 11) ; but among a variety of cancer types, the heterozygote frequency is 15% and TßR-I (6A) homozygotes, to date, have been observed only among cancer patients. Pasche et al. (9) has reported the largest study of the TßR-I (6A) variant among 851 cancers and 735 controls. The strongest association was observed with colorectal cancers, in which 4 of the 112 cases were homozygous for the TßR-I (6A) allele compared to none amongst 735 controls (P < 0.01). The study also included 48 ovarian and 152 breast cancers, and, although the TßR-I (6A) allele frequency was higher than among the controls, the number of cases was too small to provide statistically meaningful data. The aim of our study was to provide additional data concerning the possible role of the deletion TßR-I (6A) variant in breast and ovarian cancer predisposition.

The frequency of TßR-I heterozygotes among our 248 British controls was similar to that reported by van Tilborg et al. (12) in a Dutch control group, consisting of 148 people who donated blood to screen for recessive hereditary noncancer diseases (16 versus 17%). A lower frequency of TßR-I heterozygotes has been reported in an eastern United States-based population (16 versus 10%), and this may reflect ethnic differences in the distribution of the TßR-I alleles (9 , 11) . In our study, two controls were homozygous for the TßR-I (6A) allele, which is in contrast to previous studies, which did not report homozygotes among control individuals. Nevertheless, among our breast cancers, the number of TßR-I (6A) homozygotes and heterozygotes was significantly higher compared with those in the controls (OR, 1.6; 95% CI, 1.1–2.5). The number of TßR-I (6A) homozygotes among the epithelial ovarian cancers as a whole was higher than among the controls (2.0 versus 0.8%, respectively); however, the difference in allele frequency failed to reach statistical significance (P = 0.062).

There is good evidence that the different histological subtypes of ovarian cancer are distinct biological entities (10) ; and, accordingly, the data were stratified into serous, mucinous, and endometrioid/clear cell types. On this basis, the endometrioid and clear cell cancers showed a significant increase in the TßR-I (6A) allele frequency (P = 0.002). In particular, five of the six TßR-I (6A) homozygotes in the ovarian cancer group occurred among the endometrioid and clear cell subtypes, and overall, 5.4% were TßR-I (6A) homozygotes compared with only 0.8% of the controls. We have shown in previous studies that the endometrioid and clear cell ovarian cancers are likely to arise by malignant transformation of endometriosis (10) , and we were interested to see whether the TßR-I (6A) allele was also associated with this disease. The TßR-I (6A) allele frequency was indeed higher among the 98 endometriosis cases, and 2% were TßR-I (6A) homozygotes, although this failed to reach statistical significance (P = 0.09). However, our study had only a 60% power to detect an OR of 2, and larger studies into the possible association with endometriosis are warranted.

LOH analysis of the ovarian cancers demonstrated that a large proportion (68%) had lost one or both of the markers flanking the TßR-I locus. This may point to a critical involvement of TßR-I inactivation during ovarian carcinogenesis, although a more detailed analysis will be required to ascertain whether the LOH was specifically targeting the TßR-I locus. It is interesting to note that 68% of the ovarian cancers examined had LOH at 9q, but, among the 9A/6A heterozygotes, the LOH frequency was only 29%. Furthermore, we did not observe any preferential loss of the TßR-I (9A) allele among cases heterozygous for the TßR-I polymorphism. It is possible that heterozygotes, which already contain a functionally impaired allele, are less likely to undergo LOH but, in light of the small number of cases studied, this conclusion should be regarded as preliminary.

Given the potential role of germ-line variation in TßR-I in breast and ovarian cancer susceptibility, we were intrigued by a recent study reporting a recurrent CTCTGGCTGCGTGG somatic mutation in >30% of ovarian cancers (7) . Despite using both SSCP/HD and direct sequencing analysis, we failed to detect somatic alterations in exon 5 in any of the 55 ovarian or 33 breast cancers investigated. SSCP/HD analysis is efficient at identifying insertion and deletion mutations, and it is very unlikely that our analysis would have failed to identify this 2-bp insertion mutation. Indeed, SSCP was the technique used to identify the original mutation (7) . Direct genomic sequencing on a subset of the ovarian cancers also failed to identify any somatic alterations. It is unlikely that differences in the tumor cohorts could explain our failure to detect the mutation, because all the major histological subtypes of ovarian cancer were represented in our study. In any case, Wang et al. (7) reported finding mutations in all of the histological subtypes, grades, and stages of ovarian cancers. The exon 5 frameshift mutation is unusual in that it involves the insertion of one guanine residue in codon 276 and another in codon 277, apparently as a simultaneous event. The DNA sequence image of the mutation given by Wang et al. (7) was unconvincing, and it is possible that the mutation may be an artifact. Nevertheless Wang et al. provided convincing evidence that the mutation was associated with absent or reduced expression of TßR-I protein. It is likely that, by whatever mechanism, the loss of TßR-I expression is an important event in ovarian carcinogenesis.

In summary, we support previous observations that the TßR-I (6A) allele represents a cancer-predisposing factor. In our study, the TßR-I (6A) allele was associated with a 1.6-fold increased risk of breast cancer. Given that our selection criteria are characteristic of women with a genetic predisposition to breast cancer, it is unclear as to what extent this finding will apply to all breast cancer cases. With respect to ovarian cancer, the TßR-I (6A) allele appears to increase the risk of the endometrioid and clear cell subtypes but not the serous or mucinous subtypes. Although our finding of an increased risk of breast and ovarian cancer associated with the TßR-I (6A) allele agrees with Pasche et al. (9) , it is possible that chance or confounding factors, such as ethnicity and the influence of known reproductive risk factors such as oral contraceptive use, may have generated a false positive result. Consequently, it will be important to replicate our findings in larger, population-based, case-control studies. Nevertheless the high frequency of LOH at the TßR-I locus in ovarian cancers is consistent with an important role for this gene in tumor development; however, we have not been able to confirm a previous report of a somatic mutational hot spot in exon 5 of the gene.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom requests for reprints should be addressed, at Cancer Genetics Laboratory, Victorian Breast Cancer Research Consortium, Peter MacCallum Cancer Institute, Locked Bag 1. A’Beckett Street, Melbourne, Victoria 8006, Australia. Phone: 3-96561803; FAX: 3-96561411; E-mail: i.campbell{at}pmci.unimelb.edu.au

² The abbreviations used are: TGF-ß, transforming growth factor ß; TßR-I and II, TGF-ß type I and type II receptor, respectively; HD, heteroduplex; CI, confidence interval; LOH, loss of heterozygosity; OR, odds ratio; SSCP, single-stranded conformational polymorphism.

Received 3/23/01; revised 11/ 2/01; accepted 11/19/01.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Parsons R., Myeroff L. L., Liu B., Willson J. K., Markowitz S. D., Kinzler K. W., Vogelstein B. Microsatellite instability and mutations of the transforming growth factor beta-type II receptor gene in colorectal cancer. Cancer Res., 55: 5548-5550, 1995.[Abstract/Free Full Text]
2. Ohwada M., Suzuki M., Saga Y., Suzuki T., Ikeda M., Yamada M., Sato I. Mutational analysis of transforming growth factor ß receptor type II and DNA mismatch repair genes in sporadic endometrial carcinomas with microsatellite instability. Oncol Rep., 7: 789-792, 2000.[Medline]
3. Izumoto S., Arita N., Ohnishi T., Hiraga S., Taki T., Tomita N., Ohue M., Hayakawa T. Microsatellite instability and mutated type II transforming growth factor-ß receptor gene in gliomas. Cancer Lett., 112: 251-256, 1997.[Medline]
4. Kim I. Y., Ahn H. J., Zelner D. J., Shaw J. W., Sensibar J. A., Kim J. H., Kato M., Lee C. Genetic change in transforming growth factor ß (TGF-ß) receptor type I gene correlates with insensitivity to TGF-ß 1 in human prostate cancer cells. Cancer Res., 56: 44-48, 1996.[Abstract/Free Full Text]
5. Chen T., Carter D., Garrigue-Antar L., Reiss M. Transforming growth factor ß type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res., 58: 4805-4810, 1998.[Abstract/Free Full Text]
6. Cardillo M. R., Yap E., Castagna G. Molecular genetic analysis of TGF-ß1 in ovarian neoplasia. J. Exp. Clin. Cancer Res., 16: 49-56, 1997.[Medline]
7. Wang D., Kanuma T., Mizunuma H., Takama F., Ibuki Y., Wake N., Mogi A., Shitara Y., Takenoshita S. Analysis of specific gene mutations in the transforming growth factor-ß signal transduction pathway in human ovarian cancer. Cancer Res., 60: 4507-4512, 2000.[Abstract/Free Full Text]
8. Pasche B., Luo Y., Rao P. H., Nimer S. D., Dmitrovsky E., Caron P., Luzzatto L., Offit K., Cordon-Cardo C., Renault B., Satagopan J. M., Murty V. V., Massague J. Type I transforming growth factor ß receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res., 58: 2727-2732, 1998.[Abstract/Free Full Text]
9. Pasche B., Kolachana P., Nafa K., Satagopan J., Chen Y. G., Lo R. S., Brener D., Yang D., Kirstein L., Oddoux C., Ostrer H., Vineis P., Varesco L., Jhanwar S., Luzzatto L., Massague J., Offit K. TßR-I(6A) is a candidate tumor susceptibility allele. Cancer Res., 59: 5678-5682, 1999.[Abstract/Free Full Text]
10. Obata K., Morland S. J., Watson R. H., Hitchcock A., Chenevix-Trench G., Thomas E. J., Campbell I. G. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res., 58: 2095-2097, 1998.[Abstract/Free Full Text]
11. Chen T., de Vries E. G., Hollema H., Yegen H. A., Vellucci V. F., Strickler H. D., Hildesheim A., Reiss M. Structural alterations of transforming growth factor-ß receptor genes in human cervical carcinoma. Int. J. Cancer, 82: 43-51, 1999.[Medline]
12. van Tilborg A. A., de Vries A., Zwarthoff E. C. The chromosone 9q genes TGFBR1, TCS1, and ZNF189 are rarely mutated in bladder cancer. J. Pathol., 194: 76-80, 2001.[Medline]

This article has been cited by other articles:

				Y. Xu and B. Pasche TGF-{beta} signaling alterations and susceptibility to colorectal cancer Hum. Mol. Genet., April 15, 2007; 16(R1): R14 - R20. [Abstract] [Full Text] [PDF]

				H. S. Feigelson, A. V. Patel, W. R. Diver, V. L. Stevens, M. J. Thun, and E. E. Calle Transforming Growth Factor {beta} Receptor Type I and Transforming Growth Factor {beta}1 Polymorphisms Are Not Associated with Postmenopausal Breast Cancer. Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1236 - 1237. [Full Text] [PDF]

				G. Casey, P. J. Neville, X. Liu, S. J. Plummer, M. S. Cicek, L. M. Krumroy, A. P. Curran, M. R. McGreevy, W. J. Catalona, E. A. Klein, et al. Podocalyxin variants and risk of prostate cancer and tumor aggressiveness Hum. Mol. Genet., March 1, 2006; 15(5): 735 - 741. [Abstract] [Full Text] [PDF]

				W. J. Watkins, S. E. Harris, M. J. Craven, A. L. Vincent, I. M. Winship, K. Gersak, and A. N. Shelling An investigation into FOXE1 polyalanine tract length in premature ovarian failure Mol. Hum. Reprod., March 1, 2006; 12(3): 145 - 149. [Abstract] [Full Text] [PDF]

				B. Pasche, V. Kaklamani, A. Rademaker, N. Hou, H. Ahsan, and Y. Chen In Reply J. Clin. Oncol., October 20, 2005; 23(30): 7744 - 7746. [Full Text] [PDF]

				B. Pasche, T. J. Knobloch, Y. Bian, J. Liu, S. Phukan, D. Rosman, V. Kaklamani, L. Baddi, F. S. Siddiqui, W. Frankel, et al. Somatic Acquisition and Signaling of TGFBR1*6A in Cancer JAMA, October 5, 2005; 294(13): 1634 - 1646. [Abstract] [Full Text] [PDF]

				Y. Bian, T. Caldes, J. Wijnen, P. Franken, H. Vasen, V. Kaklamani, K. Nafa, P. Peterlongo, N. Ellis, J. A. Baron, et al. TGFBR1{star}6A May Contribute to Hereditary Colorectal Cancer J. Clin. Oncol., May 1, 2005; 23(13): 3074 - 3078. [Abstract] [Full Text] [PDF]

				V. G. Kaklamani, L. Baddi, J. Liu, D. Rosman, S. Phukan, C. Bradley, C. Hegarty, B. McDaniel, A. Rademaker, C. Oddoux, et al. Combined Genetic Assessment of Transforming Growth Factor-{beta} Signaling Pathway Variants May Predict Breast Cancer Risk Cancer Res., April 15, 2005; 65(8): 3454 - 3461. [Abstract] [Full Text] [PDF]

				V. G. Kaklamani, N. Hou, Y. Bian, J. Reich, K. Offit, L. S. Michel, W.S. Rubinstein, A. Rademaker, and B. Pasche TGFBR1*6A and Cancer Risk: A Meta-Analysis of Seven Case-Control Studies J. Clin. Oncol., September 1, 2003; 21(17): 3236 - 3243. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baxter, S. W. Articles by Campbell, I. G. Search for Related Content PubMed PubMed Citation Articles by Baxter, S. W. Articles by Campbell, I. G.